Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyOscar Health prenatal aneuploidy coverage update |…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy N/A

    Prenatal Testing for Fetal Aneuploidy

    Customize your policy alerts

    Sign up for all Oscar Health policy alerts

    Know when Oscar Health releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Oscar Health's coverage and clinical guidance for prenatal screening and diagnostic tests to assess fetal aneuploidy (common trisomies and sex chromosomes) for pregnant individuals; applies to providers submitting claims to Oscar Health.

    Policy Summary
    PayerOscar Health
    PolicyPrenatal Testing for Fetal Aneuploidy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization and document gestational age, maternal BMI, indication, and test name when ordering NIPS; confirm positive NIPS results with diagnostic testing.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    13-14 wksfirst-trimester window
    15-22 wkssecond-trimester window
    ≥10 wksNIPS coverage earliest gestation
    T13,T18,T21primary aneuploidies
    up to 24%no-call risk (high BMI)
    81420–81509procedure codes listed

    Coverage Criteria for Prenatal Screening and Diagnostic Tests

    inv-01: Screening tests that meet criteria

    Covered when ANY one of the following screening strategies is requested by a pregnant individual seeking information on fetal aneuploidy risk:

    Covered screening options: a) First-trimester (11-14 weeks) screening incorporating maternal serum markers (hCG, PAPP-A) with nuchal translucency (NT). b) Second-trimester (15-22 weeks) screening incorporating triple (hCG, AFP, uE3 with NT) or quad (hCG, AFP, uE3, DIA with NT) maternal serum markers. c) Integrated first- (11-14 wk) and second- (15-22 wk) trimester screening (PAPP-A with NT plus quad markers). d) Sequential first- and second-trimester screening (PAPP-A, hCG with NT then quad markers). e) Contingent screening (first-trimester PAPP-A, hCG with NT; if positive, follow with quad markers).

    inv-02: Noninvasive prenatal screening (NIPS/NIPT)

    Covered when ALL of the following are met:

    NIPS coverage criteria: NIPS to detect aneuploidy of chromosomes 13, 18, 21, X, and Y for singleton or twin pregnancies of at least 10 weeks gestation.
    Assay validity conditions: Gestational age and fetal fraction sufficient for assay validity (cffDNA usually detectable by 6–7 weeks; fetal fraction generally ≥3–4% by 10 weeks).
    Screening (not diagnostic): Test is used and interpreted as a screening tool and not as a diagnostic test; positive results require confirmatory diagnostic testing (CVS or amniocentesis with karyotype or microarray).

    inv-03: Diagnostic testing that meets criteria

    Covered when performed to confirm equivocal or positive screening results or when diagnostic confirmation is sought:

    Karyotyping of fetal cells obtained via chorionic villus sampling (CVS) or amniocentesis to confirm fetal aneuploidy meets criteria.
    Chromosomal microarray/diagnostic testing: Chromosomal microarray and other diagnostic cytogenetic methods (when clinically indicated to confirm screening results or evaluate abnormal ultrasound findings) meet criteria.

    inv-04: Screening/tests that do NOT meet criteria

    The following are explicitly not covered:

    Not covered tests and situations: a) 'Penta' screen (adds hyperglycosylated hCG) does not meet criteria. b) Parallel or simultaneous testing with multiple screening methodologies. c) Screening for higher-order multiple gestations. d) Repeat screening after negative results. e) Detection of other chromosomal abnormalities (microdeletions, unbalanced translocations, deletions, duplications) not addressed above. f) Determination of fetal sex. g) Single cell genotyping in trophoblasts isolated from maternal serum (e.g., Luna Prenatal Test) for diagnosis does not meet criteria.

    inv-05: Appropriate use of NIPS/NIPT (screening)

    Covered as a screening modality when used and interpreted as a non-diagnostic prenatal screen for common fetal aneuploidies, with required follow-up for positives:

    Core conditions for appropriate use: (1) Test is used as a screening tool for fetal aneuploidy (e.g., trisomies 21, 18, 13) and not as a diagnostic test; (2) Gestational age and fetal fraction are sufficient for assay validity (cffDNA usually detectable by 6–7 weeks and fetal fraction generally >=3–4% by 10 weeks); (3) Positive NIPS results are confirmed by diagnostic testing (CVS or amniocentesis with karyotype or microarray); (4) Ultrasound findings suggesting fetal anomalies or discordant findings prompt consideration of invasive diagnostic testing rather than reliance on NIPS alone)

    Sources: chunks 18,21,23,31

    inv-06: Covered with clinical criteria and counseling

    Covered when clinical practice follows professional society recommendations; key decision nodes:

    Offer screening and diagnostic options to all patients: Prenatal genetic screening (serum screening with or without NT ultrasound or cell-free DNA) and diagnostic testing (CVS or amniocentesis) should be discussed and offered to all pregnant individuals regardless of maternal age or risk; patients may accept or decline.

    ACOG/SMFM; NSGC; ACMG

    Single screening approach: If screening is accepted, patients should have one prenatal screening approach and should not have multiple screening tests performed simultaneously.

    ACOG/SMFM

    Positive screening follow-up: Patients with a positive screening test result should undergo genetic counseling, comprehensive ultrasound evaluation, and be offered diagnostic testing to confirm results.

    ACOG/SMFM; NSGC; ISPD

    Oscar’s policy excludes certain screening scenarios. Screening for higher-order multiple gestation pregnancies (e.g., triplets or greater) is explicitly not covered. The policy also excludes parallel or simultaneous testing with multiple screening methodologies for the same pregnancy and repeat screening after a negative result. These limits are intended to avoid redundant or unvalidated combinations of tests and to preserve a single, clinically appropriate screening approach per pregnancy.

    NIPS does not assess neural tube defects and will not detect many other chromosomal rearrangements or structural variants. NIPS also cannot determine the cause of aneuploidy (for example, it cannot distinguish an extra chromosome from an unbalanced Robertsonian translocation or high‑level mosaicism), and some discordant results may reflect confined placental mosaicism. Additionally, insufficient fetal fraction (more likely at <10 weeks gestation or with high maternal BMI) can produce no‑call or less reliable results and was associated with discordant findings in SNP‑based assays.

    Professional guidance informs scope of testing. ACOG notes that while other autosomal trisomies (for example, trisomy 16 or 22) can technically be tested, ACOG recommends against routine screening for trisomies 16 and 22 because validated clinical data are lacking to support population screening for these aneuploidies.

    Noninvasive prenatal screening is a screening, not a diagnostic, test. The FDA and the policy emphasize that NIPS results alone should not be used to definitively diagnose chromosomal abnormalities. When clinical suspicion exists (abnormal ultrasound or positive screen), diagnostic confirmation with invasive testing (CVS or amniocentesis) and cytogenetic or microarray analysis is recommended before making definitive clinical decisions.

    Certain novel or proprietary diagnostic approaches are not supported. The use of single‑cell genotyping of trophoblasts isolated from maternal serum (for example, the Luna Prenatal Test) for the diagnosis of fetal aneuploidy is considered not medically necessary / does not meet criteria because sufficient published evidence demonstrating benefit for diagnosis is lacking.

    NIPS cannot replace invasive diagnostic testing or comprehensive ultrasound when definitive diagnosis is required. The policy cites evidence that SNP‑based NIPS cannot be used as a standalone diagnostic test without ultrasound correlation or invasive confirmation, and that NIPS may miss or misclassify findings due to placental‑fetal discordance or low fetal fraction. When diagnostic accuracy is required, offer CVS or amniocentesis with karyotype or chromosomal microarray.

    Regulatory authorities caution about NIPS limitations. In an April 2021 FDA safety communication the agency reiterated that many NIPS assays are laboratory‑developed tests not reviewed by the FDA and can give false results; the FDA advised that these tests be used for screening only and that results should be discussed with a genetic counselor or other health care provider and confirmed with diagnostic testing when indicated.

    Procedure Codes and Coding Guidance

    Applicable CPT/HCPCS Procedure CodesCPT
    81420Fetal chromosomal aneuploidy (eg, trisomy 21, monosomy X) genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21.
    81422Fetal chromosomal microdeletion(s) genomic sequence analysis (eg, DiGeorge syndrome, Cri-du-chat syndrome), circulating cell-free fetal DNA in maternal blood.
    81507Fetal aneuploidy (trisomy 21, 18, and 13) DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy.
    Covered CPT Codes (NIPS / cfDNA)CPTCovered
    81420Fetal chromosomal aneuploidy genomic sequence analysis panel, circulating cell-free fetal DNA in maternal blood, must include analysis of chromosomes 13, 18, and 21
    81422Fetal chromosomal microdeletion(s) genomic sequence analysis, circulating cell-free fetal DNA in maternal blood
    81507Fetal aneuploidy DNA sequence analysis of selected regions using maternal plasma, algorithm reported as a risk score for each trisomy
    Biochemical serum/amniotic analyte CPT CodesCPTCovered
    81508Fetal congenital abnormalities, biochemical assays of two proteins (PAPP-A, hCG [any form]), utilizing maternal serum, algorithm reported as a risk score
    81509Fetal congenital abnormalities, biochemical assays of three proteins (PAPP-A, hCG [any form], DIA), utilizing maternal serum, algorithm reported as a risk score
    82105Alpha-fetoprotein (AFP); serum
    82106Alpha-fetoprotein (AFP); amniotic fluid
    82677Estriol
    84163Pregnancy-associated plasma protein-A (PAPP-A)
    84702Gonadotropin, chorionic (hCG); quantitative
    84703Gonadotropin, chorionic (hCG); qualitative
    84704Gonadotropin, chorionic (hCG); free beta chain
    86336Inhibin A
    Cytogenetic and tissue culture CPT CodesCPTCovered
    88235Tissue culture for non-neoplastic disorders; amniotic fluid or chorionic villus cells
    88267Chromosome analysis, amniotic fluid or chorionic villus, count 15 cells, karyotype, with banding
    88269Chromosome analysis; in situ for amniotic fluid cells, count cells from 6-12 colonies
    88271Molecular cytogenetics; DNA probe, each (eg, FISH)
    88280Chromosome analysis; additional karyotypes, each study
    88285Chromosome analysis; additional cells counted, each study
    inv-18: Enlarged nuchal translucency
    Threshold>3.0 mm
    Percentile reference99th percentile of crown–rump length
    Clinical implicationEnlarged NT is independently associated with fetal aneuploidy and structural malformations
    inv-19: Suggested minimal fetal fraction detection
    Earliest detectability of cffDNAUsually detectable at 6–7 weeks (earliest reported 4.5 weeks)
    Minimal fetal fraction by 10 weeksFetal fraction comprises at least 3–4% by 10 weeks of gestation

    Provider Responsibilities, Prior Authorization, and Documentation

    Prior Authorization

    Obtain authorization and ensure medical necessity

    Services must meet authorization and medical necessity guidelines; coverage does not guarantee reimbursement and is subject to member benefit details and state residence. Providers are responsible for submission of accurate documentation of services performed and coding according to industry standard coding guidelines; failure to follow guidelines may result in denial or recoupment.

    • Coverage is contingent on meeting authorization and medical necessity for the procedure, diagnosis, and member's state of residence.
    • Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed.
    Prior Authorization

    Specify proprietary NIPS test and indication on the order

    When ordering a proprietary NIPS/NIPT assay, document the specific test name and the clinical indication. Positive screening results must be followed by diagnostic confirmation (CVS or amniocentesis) per guidelines.

    • Specify the proprietary test name (e.g., Harmony™, Panorama, MaterniT21™) on the order.

    Background and Scope

    Fetal aneuploidy refers to an abnormal number of chromosomes in the fetus. The most common clinically relevant aneuploidies addressed by prenatal screening are trisomy 21 (Down syndrome), trisomy 18, trisomy 13, and monosomy X. Prenatal screening methods (maternal serum markers with or without nuchal translucency ultrasound, and cell‑free fetal DNA/NIPS) estimate the risk that a pregnancy is affected; they do not provide a definitive diagnosis and positive screening results should be confirmed with invasive diagnostic testing (CVS or amniocentesis) and appropriate cytogenetic analysis.

    Definitions and Key Terms

    inv-38: Definition — NIPS / NIPT
    DefinitionNoninvasive prenatal screening/testing using cell-free fetal DNA from maternal plasma to estimate risk for fetal aneuploidy
    Primary useScreening modality to estimate increased or decreased risk for common aneuploidies (eg, trisomies 13, 18, 21)
    Diagnostic statusScreening test only — not diagnostic; positive results should be confirmed by invasive diagnostic testing
    inv-39: NT (nuchal translucency)
    DefinitionUltrasound measurement of the fluid-filled space at the fetal neck (nuchal translucency)
    Enlarged NT threshold>3.0 mm (99th percentile)

    Policy Revision History

    06/16/2026publicationLatest

    Original documentation published and governance approved (Origination Date/Last Review recorded 06/16/2026).

    Policy Summary
    PayerOscar Health
    PolicyPrenatal Testing for Fetal Aneuploidy
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage changes
    Effective DateOct 1, 2026
    Last ReviewJun 16, 2026
    Next Review DateJun 16, 2026
    Key ActionObtain prior authorization and document gestational age, maternal BMI, indication, and test name when ordering NIPS; confirm positive NIPS results with diagnostic testing.
    SourceLink
    On This Page
    Coverage Criteria for Prenatal Screening and Diagnostic TestsProcedure Codes and Coding GuidanceProvider Responsibilities, Prior Authorization, and DocumentationBackground and ScopeDefinitions and Key TermsPolicy Revision History
    Negative screening counseling:
    Patients with a negative screening test should be informed that risk is substantially decreased but not eliminated; they may still choose diagnostic testing later, especially if new ultrasound findings emerge.

    ACOG/SMFM

    No-call cfDNA results: Patients with cfDNA results that are not reported or are uninterpretable (no-call) should be informed of increased aneuploidy risk, receive genetic counseling, and be offered comprehensive ultrasound and diagnostic testing; repeat draw may be considered per ISPD guidance.

    ACOG/SMFM; ISPD

    Multifetal gestations: NIPS/cfDNA can be performed in twin pregnancies; performance is encouraging for trisomy 21 but less certain for trisomy 18/13; labs should consider zygosity/chorionicity for interpretation and diagnostic testing should be offered for positive results. Screening options for triplets are limited.

    ACMG; ISPD

    Use of diagnostic testing by gestational age: For low-risk patients <14 weeks consider CVS or stepwise/integrated approaches; after 14-15 weeks amniocentesis is the diagnostic option; early amniocentesis prior to 15 weeks is not recommended.

    NSGC

    Scope of cfDNA: cfDNA is the most sensitive/specific screening test for common aneuploidies but is not diagnostic; results may reflect maternal aneuploidy or disease and may miss mosaicism; other trisomies (eg, 16, 22) are not recommended for routine screening due to lack of validation.

    ACOG/SMFM; ACMG; ASRM

    Expanded cfDNA content: ACMG recommends offering NIPS for sex chromosome aneuploidies in singletons and suggests offering NIPS for 22q11.2 deletion; insufficient evidence to recommend routine screening for other CNVs or rare autosomal trisomies.

    ACMG

    Clinical noteFetal fraction increases throughout gestation and may reach up to ~50% at term
    inv-20: Fetal fraction thresholds and gestational timing
    Detectability timingcffDNA usually detectable by 6–7 weeks; earliest reported 4.5 weeks
    Typical fetal fraction benchmarkFetal fraction generally ≥3–4% by 10 weeks gestation
    Low fetal fraction implicationsLow fetal fraction (eg, <8% in one study) associated with fetal–placental discrepancies and increased false positives or no-call results; early gestational age and high maternal BMI are risk factors
    Test-failure risk in high BMIHigh maternal BMI associated with reduced fetal fraction and increased test failure (up to ~24% in one large study)
  1. Document indication for testing and plan for confirmatory diagnostic testing if screen-positive.
  2. Prior Authorization

    Prior authorization may be required for listed cfDNA CPT codes

    Prior authorization may be required for molecular/cfDNA procedure codes listed in the policy; when applicable follow payer prior authorization processes for the enumerated CPT codes.

    • Key cfDNA CPT codes listed include 81420, 81422, and 81507.
    • Confirm payer prior authorization requirements for these codes before testing.
    Prior Authorization

    Follow payer prior-authorization procedures for listed prenatal codes

    Prior authorization processes may apply to the broader set of prenatal screening and diagnostic CPT/HCPCS codes enumerated in the policy; follow payer-specific prior authorization workflows when ordering these services.

    • Codes covered by prior auth processes include 81420, 81422, 81507 and additional biochemical and cytogenetic procedure codes (see policy code list).
    • Verify prior authorization for amniocentesis/CVS and associated cytogenetic testing codes when applicable.
    Step Therapy

    Step therapy: not applicable

    No step therapy requirements are specified in this excerpt.

    Step Therapy

    Follow-up actions for no-call or low fetal-fraction NIPS

    If NIPS yields a no-call or is limited by low fetal fraction (e.g., early gestational age <10 weeks or high maternal BMI), consider alternative or additional screening or diagnostic options such as maternal serum AFP in the second trimester, repeat blood draw, or offer invasive diagnostic testing.

    • Inform patient that no-call results are associated with increased aneuploidy risk and require additional investigation.
    • Options include repeat cfDNA draw, maternal serum AFP (second trimester), comprehensive ultrasound, or CVS/amniocentesis for diagnostic confirmation.
    Note

    Use a single prenatal screening approach and document choice

    If a patient accepts screening, document and perform a single prenatal screening approach rather than multiple simultaneous screening tests per professional guidance.

    • Do not perform parallel or simultaneous screening methodologies for the same pregnancy.
    • Document the chosen screening approach in the medical record.
    Note

    FDA advisory and remaining provider actions (reserved)

    (Reserved) Consolidate any additional provider-action notes from source chunk 54 as applicable.

    • Be aware of FDA communications noting NIPS are screening tests and not diagnostic; providers should not rely on NIPS alone to diagnose chromosomal abnormalities.
    Documentation Required

    Submit accurate documentation and compliant coding

    Providers must submit accurate clinical documentation and code claims according to industry-standard guidelines; failure to provide complete and accurate documentation and correct codes may result in claim denial or recoupment.

    • Ensure coding follows CPT, ICD-10, HCPCS and payer-specific instructions when submitting claims.
    • Maintain source clinical documentation to support medical necessity.
    Documentation Required

    Document gestational age, maternal BMI, and fetal fraction when ordering/interpreting NIPS

    When ordering or interpreting NIPS, document gestational age at blood draw, maternal BMI, and fetal fraction (when reported) and include any relevant prior ultrasound findings; note that positive NIPS results require follow-up diagnostic testing (CVS or amniocentesis) for confirmation.

    • Record gestational age (cffDNA usually detectable by 6–7 weeks; fetal fraction typically ≥3–4% by 10 weeks).
    • Record maternal BMI and any ultrasound findings that could affect interpretation.
    • Document fetal fraction where provided by the lab and plan for confirmatory testing if positive.
    Documentation Required

    Document counseling, informed consent, and genetic counseling offer

    Document that prenatal genetic screening and diagnostic testing options were discussed with the patient and that informed consent and genetic counseling were offered when screening or diagnostic testing is performed.

    • Record that counseling on available screening and diagnostic options occurred and whether the patient accepted or declined testing.
    • Note if formal genetic counseling was provided or offered prior to testing.
    Documentation Required

    Document counseling on NIPS benefits, risks, limitations, and results discussion

    Document that the benefits, risks, and limitations of NIPS were discussed with the patient and that results were reviewed with a genetic counselor or other healthcare provider prior to making pregnancy management decisions.

    • Specifically document discussion of NIPS limitations and FDA advisory that NIPS are screening tests and not diagnostic.
    • Record that results and next-step recommendations (including need for diagnostic confirmation if positive) were discussed with the patient.
    Denial Risk

    Risk of denial or recoupment for coding/documentation errors

    Claims may be denied or recouped if coding/billing guidelines or current reimbursement policies are not followed or if documentation is inaccurate or incomplete.

    • Ensure adherence to payer policies and timely submission of supporting clinical documentation to avoid denials or recoupment.
    Denial Risk

    Manage and document no-call or insufficient fetal fraction results

    Samples with insufficient fetal fraction (for example early gestational age <10 weeks or high maternal BMI) can yield test failure/no-call results; no-call outcomes are associated with increased aneuploidy risk and require additional investigation and documentation.

    • Document the no-call and fetal fraction data in the chart and counsel the patient on increased aneuploidy risk.
    • Offer follow-up options: repeat draw, maternal serum AFP, comprehensive ultrasound, or invasive diagnostic testing as appropriate.
    Denial Risk

    Do not rely on NIPS alone for diagnostic decisions (FDA caution)

    The FDA warns that NIPS are screening tests and can give false results; using NIPS results alone to make diagnostic determinations or to base definitive pregnancy decisions risks inappropriate care. Providers should counsel patients accordingly and document counseling and follow-up plans.

    • Discuss FDA safety communication with patients and document that results are screening only.
    • Do not use NIPS results alone to make definitive pregnancy management decisions without confirmatory diagnostic testing.
    Denial Risk

    Offer and document confirmatory diagnostic testing for positive/equivocal NIPS

    Use of NIPS results alone to diagnose chromosomal abnormalities is not appropriate; confirmatory diagnostic testing (CVS or amniocentesis with karyotype or microarray) should be offered for positive or equivocal NIPS results and this plan should be documented.

    • Document the recommendation and patient decision regarding confirmatory invasive diagnostic testing following a positive NIPS.
    • Record that reliance solely on NIPS for diagnosis is inappropriate and note any counseling provided.
    Clinical relevance
    Increased NT in first trimester (10–13 weeks) is associated with chromosomal defects and structural malformations
    inv-40: NIPS / NIPT (alternate reference)
    Screening methodUses cell-free fetal DNA from maternal plasma to screen for fetal aneuploidy
    ScopeEstimates risk for common aneuploidies but does not assess neural tube defects
    InterpretationProvides risk estimate only; not a definitive diagnostic test
    inv-41: Confined placental mosaicism (CPM)
    DefinitionGenetic discrepancy between placenta and fetus where placental mosaicism can produce discordant results
    Implication for NIPSCPM can cause false-positive NIPS results because cffDNA is placental in origin
    Study findingIn an SNP-based NIPS study, six false positives were attributed to CPM with low fetal fraction (<8%)
    inv-42: Fetal fraction
    DefinitionProportion of cell-free fetal DNA (cffDNA) relative to total cell-free DNA in maternal plasma
    Clinical implicationsLower fetal fraction at early gestation and in high maternal BMI can lead to test failure/no-call or reduced accuracy
    Typical valuesFetal fraction ≥3–4% by 10 weeks; can reach up to ~50% at term
    inv-43: CPT 81420 definition
    CodeCPT 81420
    DescriptionFetal chromosomal aneuploidy genomic sequence analysis panel from circulating cell-free fetal DNA in maternal blood; must include analysis of chromosomes 13, 18, and 21
    Use caseApplied to NIPS/cfDNA assays for common trisomies
    inv-44: CPT 81422 definition
    CodeCPT 81422
    DescriptionFetal chromosomal microdeletion(s) genomic sequence analysis from circulating cell-free fetal DNA in maternal blood
    ExamplesIncludes microdeletions such as 22q11.2 (DiGeorge) and Cri‑du‑chat when tested by cfDNA assays
    inv-45: CPT 81507 definition
    CodeCPT 81507
    DescriptionFetal aneuploidy DNA sequence analysis of selected regions using maternal plasma; algorithm reported as a risk score for each trisomy
    Intended resultReported as a trisomy-specific risk score rather than a definitive diagnosis
    inv-46: Laboratory-developed tests (LDTs)
    DefinitionLaboratory-developed tests (LDTs) are in-house tests developed and validated by laboratories and regulated by CMS under CLIA as high-complexity tests
    Regulatory contextLDTs are not necessarily FDA-cleared or -approved; FDA has issued safety communications about NIPS limitations
    Clinical implicationLDT status means test performance is lab-validated; providers should be aware of limitations and counseling needs
    inv-47: Noninvasive prenatal screening (NIPS/NIPT)
    DefinitionNoninvasive prenatal screening using cell-free fetal DNA from maternal blood to estimate risk of fetal chromosomal abnormalities
    Key limitationNIPS/NIPT are screening tests, not diagnostic; positive results require confirmatory invasive testing (CVS or amniocentesis)
    Typical targetsCommon aneuploidies addressed include trisomies 13, 18, 21 and sex chromosome aneuploidies